Vulinacimab
Based on 1 Customer Validation
Vulinacimab (HLX06) is a human monoclonal antibody directed against human vascular endothelial growth factor receptor 2 (VEGFR-2). Vulinacimab specifically binds to and inhibits VEGFR-2, which may inhibit tumor angiogenesis and tumor cell proliferation. Vulinacimab can be used for the research of solid tumors and non-small cell lung cancer.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 99.40%
- CAS. Nr.: 2250342-36-8
- Molecular Weight:145.28 kDa
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
Alle VEGFR Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
Beschreibung
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
[1]|
VEGFR-2 |
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c nude (male; subcutaneously implanted A549 cells into both side flank to establish a xenograft model)[1]
-
Dosage:25 mg/kg
-
Administration:i.p.; twice a week for 6 weeks
-
Result:Had no antitumor activity in monotherapy.
Exhibited potent antitumor activity when used in combination with HLX07.
- Human pluripotent stem cell endothelial-cell differentiation
- Vascular/Branching Fractal Analysis
- BrdU Incorporation Assay
- Somatic Cell Culture
- CFSE Dye Dilution Proliferation Assay
- Dye-dilution cell tracking and proliferation staining
- CCK-8/WST-8 Cell Proliferation Assay
- Protocol for Cell Cycle
- Cell Counting-Based Growth Curve Assay
- Colony Formation (Clonogenic) Assay
- Cell Viability Determination by MTT Colorimetric Assay
- EdU Incorporation Assay (Click Chemistry-Based DNA Synthesis Measurement)
- Ki-67 Immunostaining Proliferation Assay
- PCNA Immunodetection Proliferation Assay
- Protocol for Cell Counting and Cell Density Analysis
- Endothelial Tube Formation Assay
- MTT Cell Proliferation Assay
- Endothelial Cell Migration/Angiogenic Sprouting Assay
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Anwendung
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized VEGFR-2 Protein, Human (HEK293, His, HY-P70552) can bind Vulinacimab. The EC50 for this effect is 4.326 ng/mL.
Chemical Information
-
CAS. Nr. 2250342-36-8
-
Appearance Liquid
-
Molecular Weight 145.28 kDa
-
Color Colorless to light yellow
-
SMILES
[Vulinacimab]
-
Synonyms
HLX06
-
Versand
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Reinheit & Dokumentation
-
Data Sheet (273 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Verweise
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)